Neurodegeneration in type 2 diabetes: Evidence from spectral-domain optical coherence tomography

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 11, 2015, Pages 6333-6338

  Chhablani, Jay ^a   Sharma, Apoorva ^a   Goud, Abhilash ^a   Peguda, Hari Kumar ^a   Rao, Harsha L ^a   Begum, Viquar Unnisa ^a   Barteselli, Giulio ^b  

^a L V PRASAD EYE INSTITUTE   (India)

^b GENENTECH INC   (United States)

Author keywords

Ganglion cells analysis; GCIPL; Idiopathic macular telangiectasia; IJRT; Mactel; Retinal ganglion cells; RNFL

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; RETINA INNER NUCLEAR LAYER; RETINA INNER PLEXIFORM LAYER; RETINA NEUROEPITHELIAL LAYER; RETINAL NERVE FIBER LAYER THICKNESS; RETROSPECTIVE STUDY; SCANNING LASER POLARIMETRY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; RETINA; RETINAL DEGENERATION; VISUAL ACUITY;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINA; RETINAL DEGENERATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84943553479     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17334     Document Type: Article

References (40)

1. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304: 649-656.
2. Verma A, Rani PK, Raman R, et al. Is neuronal dysfunction an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy. Eye. 2009;23:1824-1830.
3. Bearse MA, Jr., Adams AJ, Han Y, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retinal Eye Res. 2006;25:425-448.
4. Bronson-Castain KW, Bearse MA, Jr., Neuville J, et al. Adolescents with Type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina. 2009;29:618-626.
5. Gualtieri M, Bandeira M, Hamer RD, Damico FM, Moura AL, Ventura DF. Contrast sensitivity mediated by inferred magnoand parvocellular pathways in type 2 diabetics with and without nonproliferative retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1151-1155.
6. Greenstein VC, Thomas SR, Blaustein H, Koenig K, Carr RE. Effects of early diabetic retinopathy on rod system sensitivity. Optometr Vis Sci. 1993;70:18-23.
7. Jackson GR, Scott IU, Quillen DA, Walter LE, Gardner TW. Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy. Br J Ophthalmol. 2012;96: 699-703.
8. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638-2651.
9. Han Y, Bearse MA, Jr., Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:948-954.
10. Hardy KJ, Lipton J, Scase MO, Foster DH, Scarpello JH. Detection of colour vision abnormalities in uncomplicated type 1 diabetic patients with angiographically normal retinas. Br J Ophthalmol. 1992;76:461-464.
11. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol. 2008;586:4401-4408.
12. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783-791.
13. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791-804.
14. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Exper Ophthalmol. 2000;28:3-8.
15. Foxton RH, Finkelstein A, Vijay S, et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379-1390.
16. Brar VS, Sharma RK, Murthy RK, Chalam KV. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Molec Vision. 2010;16:1848- 1853.
17. Loduca AL, Zhang C, Zelkha R, Shahidi M. Thickness mapping of retinal layers by spectral-domain optical coherence tomography. Am J Ophthalmol. 2010;150:849-855.
18. Chhablani J, Rao HB, Begum VU, Jonnadulla GB, Goud A, Barteselli G. Retinal ganglion cells thinning in eyes with nonproliferative idiopathic macular telangiectasia type 2A. Invest Ophthalmol Vis Sci. 2015;56:1416-1422.
19. Araie M, Saito H, Tomidokoro A, Murata H, Iwase A. Relationship between macular inner retinal layer thickness and corresponding retinal sensitivity in normal eyes. Invest Ophthalmol Vis Sci. 2014;55:7199-7205.
20. Sabater AL, Velazquez-Villoria A, Zapata MA, et al. Evaluation of macular retinal ganglion cell-inner plexiform layer thickness after vitrectomy with internal limiting membrane peeling for idiopathic macular holes. BioMed Res Int. 2014;2014:458631.
21. Mwanza JC, Durbin MK, Budenz DL, et al. Profile and predictors of normal ganglion cell-inner plexiform layer thickness measured with frequency-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52:7872-7879.
22. Francoz M, Fenolland JR, Giraud JM, et al. Reproducibility of macular ganglion cell-inner plexiform layer thickness measurement with cirrus HD-OCT in normal, hypertensive and glaucomatous eyes. Br J Ophthalmol. 2014;98:322-328.
23. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98:786-806.
24. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1156-1163.
25. van Dijk HW, Kok PH, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50: 3404-3409.
26. van Dijk HW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660-3665.
27. van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2012;53:2715-2719.
28. Carrasco E, Hernandez C, de Torres I, Farres J, Simo R. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Molec Vision. 2008;14:1496-1502.
29. Carrasco E, Hernandez C, Miralles A, Huguet P, Farres J, Simo R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30:2902-2908.
30. Demir M, Oba E, Sensoz H, Ozdal E. Retinal nerve fiber layer and ganglion cell complex thickness in patients with type 2 diabetes mellitus. Indian J Ophthalmol. 2014;62:719-720.
31. Lopes de Faria JM, Russ H, Costa VP. Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol. 2002;86:725-728.
32. Leung CK, Weinreb RN, Li ZW, et al. Long-term in vivo imaging and measurement of dendritic shrinkage of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2011;52:1539-1547.
33. Moon H, Yoon JY, Lim HT, Sung KR. Ganglion cell and inner plexiform layer thickness determined by spectral domain optical coherence tomography in patients with brain lesions. Br J Ophthalmol. 2015;99:329-335.
34. Rebolleda G, Sanchez-Sanchez C, Gonzalez-Lopez JJ, Contreras I, Munoz-Negrete FJ. Papillomacular bundle and inner retinal thicknesses correlate with visual acuity in nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2015; 56:682-692.
35. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Molec Med. 2012;18:1387-1401.
36. Silva KC, Rosales MA, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes. 2009;58:1382-1390.
37. Feng Y, Wang Y, Stock O, et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS One. 2009;4:e7328.
38. Luu CD, Szental JA, Lee SY, Lavanya R, Wong TY. Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest Ophthalmol Vis Sci. 2010;51: 482-486.
39. Hernandez C, Garcia-Ramirez M, Corraliza L, et al. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2013;62:2569-2578.
40. Hernandez C, Simo R. European Consortium for the Early Treatment of Diabetic R. Somatostatin replacement: a new strategy for treating diabetic retinopathy. Curr Med Chem. 2013;20:3251-3257.